GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults | GSK

GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults | GSK

For investors and media only Issued: 10 June 2022, London UK – LSE announcement First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and above The magnitude of effect observed was consistent across RSV A and B strains, key secondary endpoints and in those aged 70 years …

GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults | GSK Read More »